Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Jeske

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Handbook of Experimental Pharmacology|December 15, 2025
Comparison of the Biologic Activity of Different Species of HeparinWalter Jeske
Seminars in Thrombosis and Hemostasis|April 16, 2004
Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primatesWalter Jeske, Jawed Fareed
Lab Animal|April 23, 2014
Response to Protocol Review scenario: Need scientific justificationAntonio Valero, Walter Jeske, Cheryl Paulus
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2013
Metabolic differences of current thienopyridine antiplatelet agentsJawed Fareed, Walter Jeske, Indermohan Thethi
Molecules (Basel, Switzerland)|February 15, 2018
Advances in Heparins and Related Research. An EpilogueJawed Fareed, Peter Bacher, Walter Jeske
Personalized Medicine|May 12, 2018
Reversal of new oral anticoagulants and personalized medicineOmer Iqbal, Walter Jeske, Jawed Fareed
Journal of the American College of Cardiology|May 3, 2008
Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunctionJoseph G Akar, Walter Jeske, David J Wilber
Drug Safety|June 20, 2003
Benefit-risk assessment of treatments for heparin-induced thrombocytopeniaHarry Messmore, Walter Jeske, William Wehrmacher, et al.
Drug, Healthcare and Patient Safety|June 22, 2013
Update on the safety and bioequivalence of biosimilars - focus on enoxaparinWalter Jeske, Jeanine M Walenga, Debra Hoppensteadt, et al.
Seminars in Respiratory and Critical Care Medicine|February 28, 2008
The future of anticoagulationDebra A Hoppensteadt, Walter Jeske, Jeanine Walenga, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Handbook of Experimental Pharmacology|December 15, 2025
Comparison of the Biologic Activity of Different Species of HeparinWalter Jeske
Seminars in Thrombosis and Hemostasis|April 16, 2004
Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primatesWalter Jeske, Jawed Fareed
Lab Animal|April 23, 2014
Response to Protocol Review scenario: Need scientific justificationAntonio Valero, Walter Jeske, Cheryl Paulus
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2013
Metabolic differences of current thienopyridine antiplatelet agentsJawed Fareed, Walter Jeske, Indermohan Thethi
Molecules (Basel, Switzerland)|February 15, 2018
Advances in Heparins and Related Research. An EpilogueJawed Fareed, Peter Bacher, Walter Jeske
Personalized Medicine|May 12, 2018
Reversal of new oral anticoagulants and personalized medicineOmer Iqbal, Walter Jeske, Jawed Fareed
Journal of the American College of Cardiology|May 3, 2008
Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunctionJoseph G Akar, Walter Jeske, David J Wilber
Drug Safety|June 20, 2003
Benefit-risk assessment of treatments for heparin-induced thrombocytopeniaHarry Messmore, Walter Jeske, William Wehrmacher, et al.
Drug, Healthcare and Patient Safety|June 22, 2013
Update on the safety and bioequivalence of biosimilars - focus on enoxaparinWalter Jeske, Jeanine M Walenga, Debra Hoppensteadt, et al.
Seminars in Respiratory and Critical Care Medicine|February 28, 2008
The future of anticoagulationDebra A Hoppensteadt, Walter Jeske, Jeanine Walenga, et al.
Pageof 7